Title:Liposomal Doxorubicin In vitro and In vivo Assays in Non-small Cell Lung
Cancer: A Systematic Review
Volume: 21
Issue: 10
Author(s): Pablo Redruello-Guerrero, Paula Córdoba-Peláez, Antonio Jesús Láinez-Ramos-Bossini, Mario Rivera-Izquierdo, Cristina Mesas, Raul Ortiz*, Jose Prados*Gloria Perazzoli
Affiliation:
- Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of
Granada, 18100 Granada, Spain
- Department of Human Anatomy and Embryology, Faculty of Medicine, University of
Granada, 18071 Granada, Spain
- Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of
Granada, 18100 Granada, Spain
- Department of Human Anatomy and Embryology, Faculty of Medicine, University of
Granada, 18071 Granada, Spain
- Instituto de Investigación
Biosanitaria de Granada (ibs. Granada), Granada, 18014 Granada, Spain
Keywords:
Doxil®, non-small lung cancer, caelyx, myocet, in vivo assay, clinical trial, systematic review.
Abstract:
Background: Liposomal Doxorubicin (Doxil®) was one of the first nanoformulations approved
for the treatment of solid tumors. Although there is already extensive experience in its use for
different tumors, there is currently no grouped evidence of its therapeutic benefits in non-small cell
lung cancer (NSCLC). A systematic review of the literature was performed on the therapeutic effectiveness
and benefits of Liposomal Doxil® in NSCLC.
Methods: A total of 1022 articles were identified in publications up to 2020 (MEDLINE, Cochrane,
Web of Science Core Collection and Scopus). After applying inclusion criteria, the number was restricted
to 114, of which 48 assays, including in vitro (n=20) and in vivo (animals, n=35 and humans,
n=6) studies, were selected.
Results: The maximum inhibitory concentration (IC50), tumor growth inhibition rate, response and
survival rates were the main indices for evaluating the efficacy and effectiveness of Liposomal DOX.
These have shown clear benefits both in vitro and in vivo, improving the IC50 of free DOX or untargeted
liposomes, depending on their size, administration, or targeting.
Conclusion: Doxil® significantly reduced cellular proliferation in vitro and improved survival in vivo
in both experimental animals and NSCLC patients, demonstrating optimal safety and pharmacokinetic
behavior indices. Although our systematic review supports its benefits for the treatment of NSCLC,
additional clinical trials with larger sample sizes are necessary to obtain more precise clinical data on
its activity and effects in humans.
